Evidence map›Paper›PMID 39971198›Full record

ArticleAmerican journal of infection control2025

Advanced photohydrolysis technology demonstrates rapid inactivation of aerosolized SARS-CoV-2 and efficacy against other respiratory viral pathogens.

Jennifer E Peel, Elizabeth Jardinella, Yue Qu, Jessica A Plante, Brooke M Mitchell, Jordyn L Walker, Roberto P Garofalo, Scott C Weaver, Kenneth S Plante, Trevor Brasel and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of infection control, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Airborne Mycobacterium tuberculosis inactivated by advanced photohydrolysis technology.Annals of clinical microbiology and antimicrobials · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jennifer E PeelDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX.
Elizabeth JardinellaInstitutional Office of Regulated Nonclinical Studies, University of Texas Medical Branch, Galveston, TX.
Yue QuDepartment of Pediatrics Clinical and Experimental Immunology and Infectious Diseases, University of Texas Medical Branch, Galveston, TX.
Jessica A PlanteDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX; World Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, TX.
Brooke M MitchellDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX; World Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, TX.
Jordyn L WalkerDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX; World Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, TX.
Roberto P GarofaloDepartment of Pediatrics Clinical and Experimental Immunology and Infectious Diseases, University of Texas Medical Branch, Galveston, TX.
Scott C WeaverDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX; World Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, TX.
Kenneth S PlanteDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX; World Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, TX.
Trevor BraselDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX; Institutional Office of Regulated Nonclinical Studies, University of Texas Medical Branch, Galveston, TX.
William S LawrenceDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX. Electronic address: wslawren@utmb.edu.

Funding

World Reference Center for Emerging Viruses and Arboviruses (WRCEVA)R24AI120942 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI WEAVER, SCOTT C · 2016 to 2024
$8.5M
NIAID NIH HHS R24 AI120942
6 · The paper itself

Abstract

Efficient, rapid means of air decontamination are needed against widespread respiratory pathogens such as SARS-CoV-2, the virus that causes COVID-19. This study demonstrated the efficacy of advanced photohydrolysis technology in significantly reducing infectious, aerosolized SARS-CoV-2, achieving over 99% viral inactivation. Proof-of-concept assessments for respiratory syncytial virus and monkeypox virus showed similar results, suggesting broad applicability. These findings highlight the potential of the novel technology to enhance air purification and infection control strategies against multiple airborne viral pathogens.

Indexed as

DecontaminationSARS-CoV-2Virus InactivationAerosolsAir MicrobiologyCOVID-19HumansAerosolsAir purificationInfection controlRespiratory pathogensViral aerosols

Identifiers

PMID39971198
PMCPMC13182500

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.